BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Brian (CFO), Cristin (Chief Commercial Officer) Key Highlights of 2025 - **Revenue Growth**: Total revenue grew by 13% in 2025, with Voxzogo revenue increasing by 26% and enzyme therapies by 9% [2][3] - **Profitability Improvement**: Earnings per share growth outpaced revenue growth, achieving over 2 times leverage on the bottom line after adjusting for special items [3] - **Amicus Acquisition**: Announcement of the acquisition of Amicus, expected to close in Q2 2026, which will add two high-growth rare disease assets to BioMarin's portfolio [3][4] 2026 Outlook - **Revenue Guidance**: Expected revenue growth in both enzyme therapies and skeletal conditions at 7%-8%, with a total revenue headwind of about 3% due to decreasing royalty and other revenues [4] - **Voxzogo Revenue Guidance**: Projected revenue for Voxzogo in 2026 is between $975 million and $1.025 billion, influenced by international market access negotiations and competitive impacts [14][15] - **Pipeline Advancements**: Anticipated phase 3 readouts for hypochondroplasia and BMN 401, with potential for significant market impact [5][47] Competitive Landscape - **Voxzogo Competition**: Voxzogo faces competition, but only 25% of its revenues are from the U.S., which is subject to competition, representing about 7% of total revenue [8][15] - **Market Positioning**: BioMarin is confident in Voxzogo's established position in the achondroplasia community, emphasizing the complexity of switching treatments for patients [7][8] Clinical Pipeline - **Hypochondroplasia**: Estimated total addressable patient population of 14,000, with a focus on increasing disease awareness and shortening diagnosis times [24][25] - **BMN 351**: A second-generation exon skipping therapy for Duchenne muscular dystrophy, showing promising early data with a target of 10% dystrophin expression [6] - **ENPP1 Deficiency**: Anticipated phase 3 data readout for BMN 401, with an estimated addressable patient population of 2,000-2,500 globally [47][48] Amicus Acquisition Impact - **Revenue Contribution**: Amicus products generated over $600 million in 2025, expected to enhance BioMarin's revenue portfolio significantly [18] - **Operational Synergies**: Anticipated operational expense synergies from integrating Amicus, with a focus on leveraging existing global capabilities [30][32] Financial Strategy - **Deleveraging Plan**: Target to reduce debt to less than 2.5 times within two years post-acquisition, with a focus on maintaining operational profitability [56][57] - **Future Business Development**: Continued interest in pipeline clinical stage transactions to enhance long-term revenue growth [58] Additional Insights - **Palynziq Expansion**: Recent label expansion for Palynziq to include adolescents, with an estimated 1,500 eligible patients in the U.S. [39][41] - **Seasonality in Revenue**: Historical trends indicate a ramp-up in revenue towards Q4, with a typical step down in Q1 due to international order timing [49][50] This summary encapsulates the key points discussed during the BioMarin Pharmaceutical FY Conference, highlighting the company's growth trajectory, competitive positioning, and strategic initiatives for the upcoming year.

Core Insights - BioMarin Pharmaceutical (BMRN) reported fourth-quarter 2025 adjusted earnings per share of 46 cents, exceeding the Zacks Consensus Estimate of 25 cents, but reflecting a 50% decline year over year due to a $119.2 million inventory write-off from the withdrawal of Roctavian from the market [1][7] - Total revenues for the fourth quarter reached $875 million, a 17% increase year over year, driven by strong sales of Voxzogo, surpassing the Zacks Consensus Estimate of $830 million [2][7] - Despite the positive revenue growth, BioMarin's shares fell 2.6% in after-hours trading, likely influenced by the decision to withdraw Roctavian [2] Financial Performance - Net product revenues were approximately $859.3 million, up 17% year over year, primarily due to increased sales from Voxzogo and other enzyme therapies [4][8] - Voxzogo sales reached $273 million, a 31% increase year over year, attributed to new patient initiations and large government orders, particularly in Latin America [4][7] - Royalty and other revenues increased by 30% year over year to over $15.2 million [5] Product Performance - Sales from enzyme therapies rose 13% year over year to $549 million, driven by higher patient demand and favorable order timing [8] - Specific product sales included Palynziq at $125 million (up 25%), Vimizim at $206 million (up 8%), Naglazyme at $120 million (up 9%), and Aldurazyme at $49 million (up 26%) [9] Strategic Decisions - BioMarin announced the voluntary withdrawal of Roctavian after failing to find a buyer, resulting in a $119.2 million charge in Q4 [1][11] - The company has restructured its organizational framework, consolidating revenues from five products under the "Enzyme Therapies" segment [8] Full-Year Results and Future Outlook - For the full year 2025, BioMarin reported total revenues of $3.22 billion, a 13% increase year over year, with earnings per share of $3.15, down 11% from the previous year [13] - For 2026, BioMarin anticipates total revenues between $3.33 billion and $3.43 billion, with a Zacks Consensus Estimate of around $3.35 billion [14] - The company expects Voxzogo sales to contribute significantly, projected between $975 million and $1.03 billion, and enzyme therapies revenues between $2.23 billion and $2.28 billion [17] Pipeline Developments - The FDA has accepted BioMarin's supplemental biologics license application for Palynziq, with a decision expected by February 28, 2026 [20] - BioMarin is advancing its CANOPY clinical program for Voxzogo, with data expected in the first half of 2026 [21] - The company plans to initiate a phase II/III study for BMN 333, a long-acting formulation for growth-related conditions, in the first half of 2026 [23]

Financial Data and Key Metrics Changes - Total revenues for 2025 grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [6][11] - Fourth quarter revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [11][12] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [14][15] Business Line Data and Key Metrics Changes - Enzyme therapies revenue increased by 9% year-over-year for 2025, with Palynziq growing by 22% and Vimizim by 7% [13][21] - Voxzogo revenue for 2025 totaled $927 million, with 73% generated outside the United States, highlighting the company's global reach [12][13] - Palynziq is expected to remain a primary growth driver in 2026, supported by an anticipated adolescent label expansion [22] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated globally by year-end [23] - The company is focusing on expanding its market presence in newly launched countries and increasing penetration in existing markets, particularly among children under two years of age [24][27] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, emphasizing the importance of international markets [26] Company Strategy and Development Direction - The company plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [7][8] - BioMarin aims to build on Voxzogo's leadership in achondroplasia and expand its indications to include hypochondroplasia [9] - The company is actively engaged in business development targeting pipeline assets to drive long-term growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain revenue growth and profitability, with expectations for high single-digit growth in enzyme therapies and Voxzogo in 2026 [17][19] - The company anticipates total revenues for 2026 to be in the range of $3.325 billion to $3.425 billion, excluding contributions from the Amicus acquisition [18] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [39][40] Other Important Information - The company recorded approximately $240 million in special items during Q4 due to the strategic decision to withdraw Roctavian from the market [14] - BioMarin secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business outlook [15][16] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [36][37] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [51] Question: Expected timing for data readouts from the phase II CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [78] Question: Voxzogo guidance and market access considerations - Management is being cautious regarding routine market access negotiations, which may impact revenue growth but also present opportunities for broader access [81]

Financial Data and Key Metrics Changes - In 2025, total revenues grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [4][10] - For Q4 2025, total revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [10][11] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [12][13] Business Line Data and Key Metrics Changes - Enzyme therapies revenue for 2025 increased by 9% year-over-year, led by 22% growth for Palynziq and 7% growth for Vimizim [11][12] - Voxzogo revenue for 2025 totaled $927 million, with approximately 73% generated outside the United States, highlighting BioMarin's global reach [11][12] - Palynziq is expected to remain the primary growth driver in the enzyme therapy portfolio, supported by an anticipated adolescent label expansion [20] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated worldwide by the end of the year [21] - The company anticipates continued high patient demand across both enzyme therapies and Voxzogo in 2026, resulting in high single-digit growth rates [15][16] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, indicating a strong international market presence [23] Company Strategy and Development Direction - BioMarin plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [5][6] - The company is focused on pipeline expansion and innovation, with several anticipated data readouts and regulatory activities planned for 2026 [26][29] - BioMarin aims to solidify its revenue growth potential and transform its cost structure to achieve a strong operating margin profile [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding Voxzogo's market presence and achieving blockbuster status [9][10] - The company anticipates that integrating Amicus's products will significantly enhance its 2026 outlook and accelerate revenue growth through the 2030s [9][16] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [38][46] Other Important Information - BioMarin made a strategic decision to withdraw Roctavian from the market, resulting in approximately $240 million in special items recorded during Q4 [12] - The company secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business and financial outlook [13][14] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [33][34] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [46][47] Question: Expected timing for data readouts from the phase 2 CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [74] Question: Voxzogo guidance and market access negotiations - Management is being cautious regarding routine market access negotiations, which may impact pricing but also provide opportunities for broader patient access [77][78]

Core Insights - BioMarin Pharmaceutical is targeting a preliminary revenue of $3.2 billion for 2025, with Voxzogo expected to contribute $920 million, reflecting a strong performance and a projected 27% year-over-year growth in Q4 [3][6] - The company is focusing on expanding Voxzogo's market presence and enhancing its enzyme therapies portfolio, alongside the strategic acquisition of Amicus, valued at $4.8 billion, which is expected to diversify and accelerate revenue growth [7][8] Revenue and Growth Projections - BioMarin anticipates Voxzogo's growth in achondroplasia will be supported by new country launches and deeper market penetration, particularly emphasizing early treatment decisions for infants [2][6] - The acquisition of Amicus is expected to be accretive within 12 months post-close and substantially accretive starting in 2027, with confidence in outperforming previous growth expectations for enzyme therapies [8][7] Strategic Focus and Pipeline Development - The company's strategy is built on three pillars: innovation, growth, and a value commitment, prioritizing pipeline programs with transformative potential, including BMN 333 and BMN 351 [5][6] - BioMarin plans to accelerate revenue through geographic expansion of Voxzogo and potential label expansions for other therapies, including Palynziq [4][6] Clinical and Regulatory Catalysts - BioMarin is preparing to file for full approval of Voxzogo with the FDA, leveraging extensive safety data and additional efficacy endpoints [11] - Upcoming regulatory actions include an FDA PDUFA date for Palynziq's adolescent label expansion and significant data readouts for BMN 351 and BMN 333 [12][10][13] Competitive Dynamics and Intellectual Property Strategy - The company is committed to defending its intellectual property for Voxzogo, including seeking orphan drug exclusivity and engaging in ongoing litigation to protect its market position [15][16] - BioMarin views BMN 333 as a potential long-term game changer for achondroplasia, based on its promising exposure profile [16]

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Event**: FY Conference held on January 12, 2026 - **CEO**: Alexander Hardy Key Industry Insights - BioMarin is a leader in genetically defined conditions with a strong track record of innovation, having six first-in-disease treatments and many best-in-disease treatments [6][7] - The company operates in 80 countries and has significant R&D capabilities and in-house manufacturing [6][7] Core Financial Highlights - Preliminary revenue for 2025 is projected at **$3.2 billion**, with a **15% CAGR** over the last two years [9][21] - Voxzogo, a treatment for achondroplasia, is expected to generate **$920 million** in revenue for 2025, reflecting a **27% year-over-year growth** [19][21] Strategic Pillars 1. **Innovation**: Focus on transformative potential in the pipeline, with key assets like 333 and 351 showing promise [8][12] 2. **Growth**: Significant growth rates driven by enzyme therapies and the expansion of Voxzogo into new indications and countries [9][10] 3. **Value Commitment**: Cost transformation efforts have identified **$500 million** in cost reductions, enhancing profitability and cash flow [10] Amicus Acquisition - BioMarin announced the acquisition of Amicus for an equity value of **$4.8 billion**, which is expected to enhance revenue growth and diversify the revenue base [14][15] - Key products from Amicus include: - **Galafold** for Fabry disease, currently available in **40 countries**, with plans to expand to BioMarin's **80-country footprint** [16][17] - **Pombiliti** for Pompe disease, currently reimbursed in **15 countries**, with potential for significant growth [18] Pipeline and R&D Updates - Upcoming catalysts include: - Filing for full approval of Voxzogo in achondroplasia [12][34] - Two phase 3 data readouts and label expansions expected within the year [12][24] - BMN 351 for Duchenne muscular dystrophy showing promising early results [24][25] - BMN 333 for achondroplasia demonstrating over **13-fold** increase in free CNP exposure [28] Market Position and Competition - BioMarin is focused on defending its market position for Voxzogo against potential competitors by leveraging its established safety profile and efficacy data [49][50] - The company has petitioned for orphan drug exclusivity to delay the approval of competing products for **three more years** [49] Future Outlook - BioMarin aims for sustained double-digit CAGR growth into the 2030s, supported by the integration of Amicus products and ongoing pipeline developments [22][37] - The company is optimistic about its ability to reach more patients and enhance treatment options through its expanded portfolio [15][51] Additional Notes - The adherence rate for Voxzogo is approximately **90%**, indicating strong patient retention [45] - The company emphasizes the importance of early diagnosis and treatment in achondroplasia, which is expected to drive future growth [39][40]

Acquisition Details - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, gaining two marketed drugs for rare diseases and a third asset in late-stage testing [1][2] - The acquisition is an all-cash deal, with BioMarin paying $14.50 per Amicus share, representing a 33% premium over Amicus' closing stock price prior to the announcement [2] Financial Impact - BioMarin anticipates that Amicus' medicines will enhance its long-term revenue growth through 2030 and beyond, with Galafold generating $371 million in revenue for Amicus in the first nine months of the year [3] - Amicus' second marketed product, a combination of Pombiliti and Opfolda, recorded $77 million in revenue during the same period [4] - If the acquisition closes, BioMarin's marketed therapies will increase to 10, contributing to a reported net product revenue of $2.3 billion from January to September, an 11% year-over-year increase [5] Strategic Fit - BioMarin's CEO described Amicus as an "exceptional strategic fit," expecting the deal to be accretive to non-GAAP diluted earnings per share within a year of closing [7] - Amicus has a potentially first-of-its-kind treatment for FSGS, an uncommon kidney disease, which could further expand BioMarin's portfolio [6]

Core Insights - Amicus is a rare disease-focused biotech company with three programs, each having a potential market opportunity of $1 billion, currently at different development stages [1] - The company is expected to turn profitable in the second half of the year and maintains a strong cash position [1] Product Performance - Galafold, the first approved product for Fabry disease, was launched in 2016 and is projected to achieve 10% to 15% growth this year, with sales exceeding $500 million [2] - Pombiliti, Opfolda, is in the early stages of its launch after receiving approval in 2023, indicating potential for future growth [2]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $169.1 million, a 19% increase compared to Q3 2024, with a 17% growth at constant exchange rates [23] - GAAP net income for Q3 2025 was $17.3 million, or $0.06 per share, compared to a net loss of $6.7 million, or $0.02 per share, in Q3 2024, marking the first quarter of positive GAAP net income in 2025 [24][25] - Non-GAAP net income for Q3 2025 was $54.2 million, or $0.18 per share, compared to $30.8 million, or $0.10 per share, in the same quarter last year [25] Business Line Data and Key Metrics Changes - Galafold revenue reached $138.3 million, up 12% at constant exchange rates and 15% in reported terms, with a year-over-year patient demand increase of 13% [10] - Pombiliti and Opfolda generated $30.7 million in revenue for Q3, a 42% increase at constant exchange rates and 45% in reported terms, with year-to-date growth of 59% at CER [14] Market Data and Key Metrics Changes - Approximately 69% of the global market share of treated Fabry patients with amenable mutations is held by Galafold [10] - The U.S. represented approximately 43% of Pombiliti and Opfolda revenue, while ex-U.S. accounted for 57% [15] Company Strategy and Development Direction - The company aims to achieve combined sales of $1 billion for its two commercial products by 2028, supported by growing diagnostic rates and patient access [7] - The company is advancing the development of DMX-200, a therapy for FSGS, with over 90% enrollment in the ACTION3 pivotal study expected to complete by year-end [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth in the Fabry and Pompe core business, driven by record demand and robust new patient starts [5] - The company anticipates positive GAAP net income for the second half of 2025 and reiterated full-year financial guidance for 2025, projecting total revenue growth of 15%-22% [26][27] Other Important Information - The company highlighted the significant unmet need in Fabry disease, with over 6,000 diagnosed patients remaining untreated, indicating a larger market opportunity for Galafold [12] - The company is focused on expanding its market presence and increasing patient compliance and adherence rates above 90% [16] Q&A Session Summary Question: Reception of Pombiliti in the U.S. and real-world evidence impact - Management noted that the label for Pombiliti has been well received, with ongoing studies expected to support label expansion for pediatric patients [32] - Real-world evidence is increasingly important in discussions with physicians, and the company plans to continue supporting publications and presentations [33][34] Question: U.S. new patient starts and revenue trajectory for 2026 - Management reported significant increases in new patient starts in Q3 and expressed confidence in continued momentum into 2025 [42] - The company is focused on expanding its sales force and enhancing real-world evidence to drive revenue growth [43] Question: Galafold patient adds from core vs. emerging countries - The growth in patient adds is primarily driven by core countries, with a significant number of naive patients being diagnosed [48][49] Question: DMX-200 candidate selection based on MCP-1 levels - Management indicated that higher MCP-1 levels correlate with more robust responses to DMX-200, and they are measuring MCP-1 throughout the phase three study [54][55] Question: Impact of Biosecure 2.0 on Pombiliti usability in the U.S. - Management expressed confidence in maintaining a stable supply from the Ireland facility and highlighted the importance of providing evidence to physicians regarding Pombiliti [59][60] Question: Timing for infantile onset Pompe disease label expansion - Management anticipates a submission for adolescent patients mid-next year, with further progress expected for infantile onset patients thereafter [66][68] Question: Commercial trajectory of Pombiliti and market share expectations - Management is confident in continued growth and aims for over 50% market share at peak for Pombiliti, with a target of exceeding $1 billion in revenue [71][72]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $169.1 million, a 19% increase compared to Q3 2024, with a 17% growth at constant exchange rates [23] - GAAP net income for Q3 2025 was $17.3 million, or $0.06 per share, compared to a net loss of $6.7 million, or $0.02 per share, in Q3 2024, marking the first quarter of positive GAAP net income in 2025 [24][25] - Non-GAAP net income for Q3 2025 was $54.2 million, or $0.18 per share, compared to $30.8 million, or $0.10 per share, in the same quarter last year [25] Business Line Data and Key Metrics Changes - Galafold revenue reached $138.3 million, up 12% at constant exchange rates and 15% in reported terms, with a year-over-year patient demand increase of 13% [10][11] - Pombiliti and Opfolda generated $30.7 million in revenue for Q3 2025, reflecting a 42% increase at constant exchange rates and 45% in reported terms, with year-to-date growth of 59% at CER [14][15] Market Data and Key Metrics Changes - The U.S. represented approximately 43% of Pombiliti and Opfolda revenue, while ex-U.S. accounted for 57% [15] - Galafold holds approximately 69% of the global market share of treated Fabry patients with amenable mutations [10] Company Strategy and Development Direction - The company aims to achieve combined sales of $1 billion for its two commercial products by 2028, supported by strong growth in patient demand and market penetration [7][8] - The company is advancing the development of DMX-200, a first-in-class therapy for FSGS, with over 90% enrollment in the ACTION3 pivotal study expected to complete by year-end [8][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth in the Fabry and Pompe core business, driven by record demand and new patient starts [5][6] - The company anticipates positive GAAP net income for the second half of 2025, reinforcing its financial discipline and growth trajectory [24][26] Other Important Information - The company is focused on expanding its market presence and improving patient access, particularly in underdiagnosed populations [12][13] - The company is working on enhancing awareness and diagnosis of Fabry disease through initiatives like the Finding Fabry campaign [13] Q&A Session Summary Question: Reception of Pombiliti label and real-world evidence impact - Management noted that the label for Pombiliti has been well received, with ongoing studies expected to support label expansion for pediatric patients [32] - Real-world evidence is increasingly important in discussions with physicians, with positive feedback on durability and effectiveness from clinical trials [34] Question: U.S. new patient starts and revenue trajectory for 2026 - Management confirmed that Q3 saw the largest net commercial demand for Pombiliti and Opfolda, with significant increases in prescriptions and improved reimbursement times [42] - The company is optimistic about continued momentum into 2025, with plans to expand into new markets and enhance real-world evidence [43] Question: Galafold patient additions from core vs. emerging countries - The growth in Galafold patient additions is primarily driven by core countries, with a significant number of naive patients being diagnosed [48] Question: DMX-200 candidate selection based on MCP-1 levels - Management indicated that while there is no defined threshold for MCP-1 levels for DMX-200 candidates, higher levels may correlate with better responses [54] Question: Impact of Biosecure 2.0 on Pombiliti usability - Management expressed confidence in maintaining a stable supply from the Ireland facility, which is expected to enhance the usability of Pombiliti in the U.S. [59] Question: Timing for infantile onset Pompe disease label expansion - Management anticipates a submission for adolescent patients by mid-next year, with further expansions for younger patients and infantile onset following [66][68] Question: Commercial trajectory of Pombiliti in 2026 - Management is confident in strong growth for Pombiliti, aiming for over 50% market share at peak, with a trajectory towards $1 billion in revenue [71][72]